Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 Clinical Trials

23 clinical trials for Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study — RECRUITING · PHASE2
• Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer — RECRUITING · PHASE2
• Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study — RECRUITING · PHASE2
• Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma — RECRUITING · PHASE1
• Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer — RECRUITING · PHASE1
• Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer — RECRUITING · PHASE2
• De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA — RECRUITING · PHASE2
• Oropharynx (OPX) Biomarker Trial — RECRUITING
• Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer — RECRUITING
• Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer — RECRUITING · PHASE1
• Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin — COMPLETED · PHASE2
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer — SUSPENDED · PHASE2
• Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin — ACTIVE_NOT_RECRUITING · PHASE1
• Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin — NOT_YET_RECRUITING · PHASE3
• A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer — TERMINATED · PHASE2
• Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer — WITHDRAWN · NA
• Study of Mucosal Sparing Adjuvant Radiotherapy After Surgical Exploration in HPV+ Head and Neck Cancer of Unknown Primaries — COMPLETED · NA
• Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner — TERMINATED · PHASE1
• Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma — TERMINATED · PHASE2

Refine this search